Bacterin Awarded Patent for Method to Produce Demineralized Bone Matrix BELGRADE, MT

Bacterin Awarded Patent

for Method to Produce Demineralized Bone

MT, November 6, 2013 -- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary

bone graft materials and coatings for medical applications, today announced that the

United States Patent and Trademark Office has issued US Patent No. 8,574,825 entitled "Process for Demineralization of Bone

Matrix with Preservation of Natural Growth Factors." The issued claims in the patent are for a method to produce a demineralized

cancellous bone matrix, such as Bacterin's OsteoSponge product line. Bacterin has

a pending divisional application in the United States to pursue protection on other aspects of its bone demineralization technology

and is pursuing protection on related applications in Canada, Europe, and Korea.

Gregory Juda, Bacterin's CSO, commented

"We are pleased to receive this patent that protects our proprietary Demineralized Bone products and recognizes the long

term innovation of our Company. This patent further substantiates our core competency in demineralized bone matrix technology

and we are committed to maintaining our role as a leader in advancing orthobiologic technology."

The OsteoSponge technology

is two-fold; it allows for the allograft comprised of human bone to become compressible, while maintaining the spectrum of native

growth factors inherent to bone. These growth factors are essential for the tissue regeneration process in the patients'

body. Because of the compressible handling of the scaffold, and the presence of growth factors, Bacterin has been able to show

fusion rates greater than 97 percent in peer reviewed, published studies. Bacterin was the first company to commercialize a compressible

DBM sponge, marketed specifically for its handling characteristics, osteoconductive architecture, and osteoinductive properties

for orthopedic bone grafting applications.

Bacterin International Holdings

Bacterin International

Holdings, Inc. (NYSE MKT: BONE) develops, manufactures and markets biologics products to domestic and international markets. These

products are used in a variety of applications including enhancing fusion in spine surgery, relief of back pain, promotion of bone

growth in foot and ankle surgery, promotion of cranial healing following neurosurgery and subchondral repair in knee and other

Bacterin's Medical Device

division develops, employs, and licenses coatings for various medical device applications. For further information, please visit

Important Cautions Regarding Forward-looking Statements

This news release contains certain disclosures

that may be deemed forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are

subject to significant risks and uncertainties. Forward-looking statements include statements that are predictive in nature, that

depend upon or refer to future events or conditions, or that include words such as "continue," "efforts," "expects,"

"anticipates," "intends," "plans," "believes," "estimates," "projects,"

"forecasts," "strategy," "will," "goal," "target," "prospects," "potential,"

"optimistic," "confident," "likely," "probable" or similar expressions or the negative

thereof. Statements of historical fact also may be deemed to be forward-looking statements. We caution that these statements by

their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors,

including, among others: the Company's ability to meet its existing and anticipated contractual obligations, including financial

covenant and other obligations contained in the Company's secured lending facility; the Company's ability to manage

cash flow and achieve profitability; the Company's ability to develop, market, sell and distribute desirable applications, products

and services and to protect its intellectual property; the ability of the Company's sales force to achieve expected results; the

ability of the Company's customers to pay and the timeliness of such payments; the Company's ability to obtain financing as and

when needed; changes in consumer demands and preferences; the Company's ability to attract and retain management and employees

with appropriate skills and expertise; the Company's ability to successfully conclude government investigations; the impact

of changes in market, legal and regulatory conditions and in the applicable business environment, including actions of competitors;

and other factors. Additional risk factors are listed in the Company's Annual Report on Form 10-K and Quarterly Reports on Form

10-Q under the heading "Risk Factors." The Company undertakes no obligation to release publicly any revisions to any

forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated

events, except as required by law.